All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 15, 2022
Home » Blogs » BioWorld MedTech Perspectives » Meaningless use; the current state of healthcare IT

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Meaningless use; the current state of healthcare IT

July 22, 2013
By Mark McCarty
No Comments

The good ol' Trash 80: As relevant as meaningful use?
The good ol' Trash 80: As relevant as meaningful use?

It’s tempting to amuse oneself about healthcare IT by juxtaposing it with a more or less dusty fixture of pop culture. For instance, you can sing the Bob Seger song “Beautiful loser,” and substitute the words “meaningful user” to parody things, but there are huge problems with healthcare IT, and they’re not particularly funny.

For instance, the head honcho at the Office of the National Coordinator appeared on Capitol Hill last week and gave the Senate Finance Committee a glowing report on healthcare IT adoption. However, Farzad Mostashari informed the committee (only after someone asked) that 10,000 providers had dropped out of the meaningful use program, a seemingly small number when compared with the 300,000 providers that had enrolled.

The problem? The taxpayer has coughed up $15 billion in incentives to those 300,000 providers, which is an average of about $50,000. Take those 10,000 departing providers and multiply them by $50,000, and you have something like half a billion dollars down the rabbit hole.

As the saying goes, a million here, a million there … who says Senator Dirksen is irrelevant?

Even the providers that are still on board are carping about meaningful use standards, however, a sure sign the HITECH Act was ambitious beyond rational thinking. Sen. Orrin Hatch recently proposed that ONC slow down on the meaningful user program, but he wasn’t the first. A group of six senators made the same suggestion in April.

Let’s not forget that more providers will dump the whole meaningful use thing when the ICD-10 squeeze starts to feel like a python, and you have the makings of a bona fide exercise in absurdity, even by government standards.

Do as I say, not as I do

The workflow debate is still cruising along, with ONC’s Mostashari repeatedly asserting that providers will have to adjust their workflows to the software rather than the other way around. At a July 9 briefing in Washington, he said of existing workflow patterns: “If you merely pave over the cowpath, you have a streetmap that looks like Boston,” which sounds like a great description of the government's approach to interoperability.

Mostashari also compared this workflow dilemma to factory workflows upon the introduction of electricity. I reminded him that the typical doctor has much more influence over the HIT workflow debate than the typical 19th Century factory worker had over his working conditions. Mostashari heard me, but was undaunted. He remarked that the government is “only about 5% of the way through” the process of forcing a change of workflow onto practitioners.

Apparently Mostashari hasn’t heard about the influence MDs have on policy in this town. I wonder whether he likes his humble pie served a la mode.

The final ingredient: Interopera-bull

This interoperability discussion has wandered like a deranged ruminant for nearly a decade, and now we hear that the market, not government, will determine what constitutes interoperability. Seems to me we could have left it up to the market back in 2005, when HHS secretary Mike Leavitt first started yakking about it.

Still, government’s concession on the interoperability clanger serves as a nice denouement for what has been much ado about not very much so far. The taxpayer is on the hook for $15 billion to date, and another $15 billion or more to come. It strikes me that even our government could have found a more meaningful way to squander $30 billion.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 12, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 12, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing